The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Primary Membranous Nephropathy
Open accessAbstract
Membranous nephropathy (MN) is a unique glomerular lesion that is the most common cause of idiopathic nephrotic syndrome in nondiabetic white adults. About 80% of cases are renal limited (primary MN, PMN) and 20% are associated with other systemic diseases or exposures (secondary MN). This review focuses only on PMN. Most cases of PMN have circulating IgG4 autoantibody to the podocyte membrane antigen PLA2R (70%), biopsy evidence PLA2R staining indicating recent immunologic disease activity despite negative serum antibody levels (15%), or serum anti-THSD7A (3%–5%). The remaining 10% without demonstrable anti-PLA2R/THSd7A antibody or antigen likely have PMN probably secondary to a different, still unidentified, anti-podocyte antibody. Considerable clinical and experimental data now suggests these antibodies are pathogenic. Clinically, 80% of patients with PMN present with nephrotic syndrome and 20% with non-nephrotic proteinuria. Untreated, about one third undergo spontaneous remission, especially those with absent or low anti-PLA2R levels, one-third progress to ESRD over 10 years, and the remainder develop nonprogressive CKD. Proteinuria can persist for months after circulating anti-PLA2R/THSD7A antibody is no longer detectable (immunologic remission). All patients with PMN should be treated with supportive care from the time of diagnosis to minimize protein excretion. Patients with elevated anti-PLA2R/THSD7A levels and proteinuria >3.5 g/d at diagnosis, and those who fail to reduce proteinuria to <3.5 g after 6 months of supportive care or have complications of nephrotic syndrome, should be considered for immunosuppressive therapy. Accepted regimens include steroids/cyclophosphamide, calcineurin inhibitors, and B cell depletion. With proper management, only 10% or less will develop ESRD over the subsequent 10 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
M-Type Phospholipase A 2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy
Beck, L. H., Bonegio, R. G. B., Lambeau, G., Beck, D. M., Powell, D. W., Cummins, T. D., Klein, J. B., & Salant, D. J. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810457 · Cited by 2,347
Faul, C., Donnelly, M., Merscher-Gomez, S., Chang, Y. H., Franz, S., Delfgaauw, J., Chang, J.-M., Choi, H. Y., Campbell, K. N., Kim, K., et al. (2008) · Nature Medicine · doi:10.1038/nm.1857 · Cited by 991
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.9 · Cited by 966
Thrombospondin Type-1 Domain-Containing 7A in Idiopathic Membranous Nephropathy
Tomas, N. M., Beck, L. H., Meyer-Schwesinger, C., Seitz-Polski, B., Ma, H., Zahner, G., Dolla, G., Hoxha, E., Helmchen, U., Dabert-Gay, A.-S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409354 · Cited by 945
KDIGO Clinical Practice Guideline for Glomerulonephritis
Eckardt, K., & Kasiske, B. L. (2012) · Cited by 893
Antenatal Membranous Glomerulonephritis Due to Anti–Neutral Endopeptidase Antibodies
Debiec, H., Guigonis, V., Mougenot, B., Decobert, F., Haymann, J.-P., Bensman, A., Deschênes, G., & Ronco, P. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012895 · Cited by 528
Risk HLA-DQA1 and PLA 2 R1 Alleles in Idiopathic Membranous Nephropathy
Stanescu, H. C., Arcos-Burgos, M., Medlar, A., Bockenhauer, D., Kottgen, A., Dragomirescu, L., Voinescu, C., Patel, N., Pearce, K., Hubank, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009742 · Cited by 523
Long-Term Exposure to Air Pollution and Increased Risk of Membranous Nephropathy in China
Xu, X., Wang, G., Chen, N., Lu, T., Nie, S., Xu, G., Zhang, P., Luo, Y., Wang, Y., Wang, X., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016010093 · Cited by 476
Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up
Dahan, K., Debiec, H., Plaisier, E., Cachanado, M., Rousseau, A., Wakselman, L., Michel, P.-A., Mihout, F., Dussol, B., Matignon, M., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040449 · Cited by 439
Ruggenenti, P., Debiec, H., Ruggiero, B., Chianca, A., Pellé, T., Gaspari, F., Suardi, F., Gagliardini, E., Orisio, S., Benigni, A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070640 · Cited by 376
A Proposal for a Serology-Based Approach to Membranous Nephropathy
De Vriese, A. S., Glassock, R. J., Nath, K. A., Sethi, S., & Fervenza, F. C. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016070776 · Cited by 372
Pathophysiological advances in membranous nephropathy: time for a shift in patient's care
Ronco, P., & Debiec, H. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60731-0 · Cited by 369
Kanigicherla, D., Gummadova, J., McKenzie, E. A., Roberts, S. A., Harris, S., Nikam, M., Poulton, K., McWilliam, L., Short, C. D., Venning, M., et al. (2013) · Kidney International · doi:10.1038/ki.2012.486 · Cited by 347
Larsen, C. P., Messias, N. C., Silva, F. G., Messias, E., & Walker, P. D. (2013) · Modern Pathology · doi:10.1038/modpathol.2012.207 · Cited by 248
A Mechanism for Cancer-Associated Membranous Nephropathy
Hoxha, E., Wiech, T., Stahl, P. R., Zahner, G., Tomas, N. M., Meyer-Schwesinger, C., Wenzel, U., Janneck, M., Steinmetz, O. M., Panzer, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1511702 · Cited by 212
Membranous nephropathy: recent travels and new roads ahead
Beck, L. H., & Salant, D. J. (2010) · Kidney International · doi:10.1038/ki.2010.34 · Cited by 200
Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial
Howman, A., Chapman, T. L., Langdon, M. M., Ferguson, C., Adu, D., Feehally, J., Gaskin, G. J., Jayne, D. R., O'Donoghue, D., Boulton-Jones, M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61566-9 · Cited by 196
Cosio, F. G., & Cattran, D. C. (2017) · Kidney International · doi:10.1016/j.kint.2016.08.030 · Cited by 159
The etiology of glomerulonephritis: roles of infection and autoimmunity
Couser, W. G., & Johnson, R. J. (2014) · Kidney International · doi:10.1038/ki.2014.49 · Cited by 151
Self-citationLeeaphorn, N., Kue-A-Pai, P., Thamcharoen, N., Ungprasert, P., Stokes, M. B., & Knight, E. L. (2014) · American Journal of Nephrology · doi:10.1159/000364782 · Cited by 114
Radice, A., Trezzi, B., Maggiore, U., Pregnolato, F., Stellato, T., Napodano, P., Rolla, D., Pesce, G., DʼAmico, M., Santoro, D., et al. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.10.004 · Cited by 111
Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy
Lee, T., Biddle, A. K., Lionaki, S., Derebail, V. K., Barbour, S. J., Tannous, S., Hladunewich, M., Hu, Y., Poulton, C. J., Mahoney, S., et al. (2013) · Kidney International · doi:10.1038/ki.2013.476 · Cited by 106
Ramachandran, R., Hn, H. K., Kumar, V., Nada, R., Yadav, A. K., Goyal, A. K., Kumar, V., Rathi, M., Jha, V., Gupta, K. L., et al. (2015) · Nephrology · doi:10.1111/nep.12569 · Cited by 102
MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy.
Cui, Z., Xie, L.-J., Chen, F.-J., Pei, Z.-Y., Zhang, L.-J., Qu, Z., Huang, J., Gu, Q.-H., Zhang, Y.-M., Wang, X., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016020114 · Cited by 99
Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy
Thompson, A., Cattran, D., Blank, M. J., & Nachman, P. H. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010091 · Cited by 95
Immunology of membranous nephropathy: from animal models to humans
Sinico, R. A., Mezzina, N., Trezzi, B., Ghiggeri, G. M., & Radice, A. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12729 · Cited by 87
Patients with primary membranous nephropathy are at high risk of cardiovascular events
Lee, T., Derebail, V. K., Kshirsagar, A. V., Chung, Y., Fine, J. P., Mahoney, S., Poulton, C. J., Lionaki, S., Hogan, S. L., Falk, R. J., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.041 · Cited by 81
HLA-DRB1*15:01 and HLA-DRB3*02:02 in PLA2R-Related Membranous Nephropathy
Le, W., Shi, J., Zhang, T., Liu, L., Qin, H.-Z., Liang, S., Zhang, Y., Zheng, C.-X., Jiang, S., Qin, W., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060644 · Cited by 80
Complement-Mediated Cellular Injury
Takano, T., Elimam, H., & Cybulsky, A. V. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.009 · Cited by 74
THSD7A expression in human cancer
Stahl, P. R., Hoxha, E., Wiech, T., Schröder, C., Simon, R., & Stahl, R. A. K. (2016) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22440 · Cited by 65
De Novo Glomerular Diseases after Renal Transplantation
Ponticelli, C. E., Moroni, G. L., & Glassock, R. J. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12571213 · Cited by 64
Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab
Waldman, M. A., Beck, L. H., Braun, M., Wilkins, K. J., Balow, J. E., & Austin, H. A. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.05.002 · Cited by 60
Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not?
Cravedi, P., Remuzzi, G., & Ruggenenti, P. L. (2014) · Nephron Clinical Practice · doi:10.1159/000368589 · Cited by 55
Dong, H., Wang, Y., Cheng, X., Wang, G., Sun, L., Cheng, H., & Chen, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156263 · Cited by 54
Alkylating agents in membranous nephropathy: efficacy proven beyond doubt
Hofstra, J. M., & Wetzels, J. F. M. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq017 · Cited by 51
Phospholipase A2 Receptor Antibodies in Membranous Nephropathy: Unresolved Issues
Hofstra, J. M., & Wetzels, J. F. M. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014010091 · Cited by 38
Pharmacological treatment of primary membranous nephropathy in 2016
van de Logt, A.-E., Hofstra, J. M., & Wetzels, J. F. M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1225497 · Cited by 38
Cybulsky, A. V., Walsh, M. W., Knoll, G. A., Hladunewich, M., Bargman, J. M., Reich, H. N., Humar, A., Samuel, S. M., Bitzan, M. M., Zappitelli, M., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.12.001 · Cited by 36
Kittanamongkolchai, W., Cheungpasitporn, W., & Zand, L. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw045 · Cited by 31
Cited by
Aging Biomarker Consortium, Bao, H., Cao, J., Chen, M., Chen, M., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 376
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy
Sethi, S., Debiec, H., Madden, B., Charlesworth, M. C., Morelle, J., Gross, L., Ravindran, A., Buob, D., Jadoul, M., Fervenza, F. C., et al. (2020) · Kidney International · doi:10.1016/j.kint.2019.09.014 · Cited by 360
Chen, D.-Q., Cao, G., Chen, H., Argyopoulos, C. P., Yu, H., Su, W., Chen, L., Samuels, D. C., Zhuang, S., Bayliss, G. P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09329-0 · Cited by 270
Immunology of the ageing kidney
Sato, Y., & Yanagita, M. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0185-9 · Cited by 126
Metadata
- Authors
- Couser, W. G.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2017-05-26
- Volume
- 12
- Issue
- 6
- Pages
- 983-997
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- OpenAlex
- W2617482626
- Cited by
- 690
- References
- 39
- FWCI
- 30.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.